First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
"Management emphasized, 'Our focus on innovation and market expansion is driving our growth trajectory.'"
Moat: Kalbe Farma's strong brand recognition and extensive distribution network provide a durable competitive advantage.
value - Given its low valuation metrics and strong fundamentals, Kalbe Farma is attractive to value investors seeking stable growth.
Low - The company's low debt levels (Debt/Equity of 0.01) minimize sensitivity to interest rate changes…
Watch on earnings: Regulatory approval timelines for new products, Market share in the Indonesian pharmaceutical sector, Raw material cost trends.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $35.04T to $37.85T as kalbe farma's recent expansion into the asean market could increase revenue by an estimated 20% over the next two years.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.